Ovarian Cancer Gene Therapy Specialist Is One of Three Researchers Sharing $1.3 Million in Grants

Ovarian Cancer Gene Therapy Specialist Is One of Three Researchers Sharing $1.3 Million in Grants
Three American scientists are sharing $1.3 million from the Alliance for Cancer Gene Therapy to investigate whether immunotherapy and gene therapy can combat three of the most life-threatening forms of cancer: ovarian, brain and bone cancer. The three are Drs. Daniel Powell Jr. of the University of Pennsylvania's Perelman School of Medicine, Nori Kasahara of the University of Miami's Sylvester Comprehensive Cancer Center, and Seth Pollack of Seattle's Fred Hutchinson Cancer Research Center. “We have big hopes for these grants,” John Walter, the alliance's president and chief executive officer, said in a press release. “The recent FDA approval of the first gene therapy treatment to come out of this research, Kymriah, validates the promise of this science. With these three new clinical investigator grants, we hope to see similar results with immunotherapy and virotherapy [virus-based therapies] in treating hard-to-combat solid tumor cancers.” Powell will work on CAR T-cell therapies for ovarian cancer. He will use his grant to enroll nine patients in a new clinical trial of the treatment. CAR T-cell therapy involves gathering a patient's own immune T-cells, engineering them in a lab to recognize cancer cells, then reintroducing them to the patient. The full scientific name for CAR T-cells is chimeric antigen receptor T-cells. Kasahara will investigate viral therapies for brain cancer, or glioblastoma, and Pollack immunotherapies  against bone cancer, or sarcoma. The Alliance for Cancer Gene Therapy grants will allow "these scientists to advance their research
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *